160 results
Page 4 of 8
PRER14A
8k6dnp x990534
8 Dec 20
Preliminary revised proxy
4:11pm
8-K
EX-2.1
ggq2 8tgti3z18oj5rs
28 Oct 20
Acquisition includes clinical stage anti-IGF-1R monoclonal antibody, VRDN-001, intended for Company plans to use private placement financing proceeds of $91 million to advance multiple
9:28am
8-K
EX-10.2
uo4ys
28 Oct 20
Acquisition includes clinical stage anti-IGF-1R monoclonal antibody, VRDN-001, intended for Company plans to use private placement financing proceeds of $91 million to advance multiple
9:28am
8-K
EX-99.1
9i6pmyszo11d65lk
28 Oct 20
Acquisition includes clinical stage anti-IGF-1R monoclonal antibody, VRDN-001, intended for Company plans to use private placement financing proceeds of $91 million to advance multiple
9:28am
8-K
cr4ug
28 Oct 20
Acquisition includes clinical stage anti-IGF-1R monoclonal antibody, VRDN-001, intended for Company plans to use private placement financing proceeds of $91 million to advance multiple
9:28am
8-K
EX-99.2
bsuume
28 Oct 20
Acquisition includes clinical stage anti-IGF-1R monoclonal antibody, VRDN-001, intended for Company plans to use private placement financing proceeds of $91 million to advance multiple
9:28am
8-K
mftca9eaj3r07o
22 May 20
Submission of Matters to a Vote of Security Holders
4:15pm